US Tech 100

18,065.60

-0.08%

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

AFMD

Affimed NV (AFMD)

Affimed NV

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:AFMD

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
05/14/2024	9:05AM	GlobeNewswire Inc.	Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress	NASDAQ:AFMD	Affimed NV
04/24/2024	3:05AM	GlobeNewswire Inc.	Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology	NASDAQ:AFMD	Affimed NV
03/28/2024	5:30AM	GlobeNewswire Inc.	Affimed Reports 2023 Financial Results and Operational Progress	NASDAQ:AFMD	Affimed NV
03/21/2024	5:30AM	GlobeNewswire Inc.	Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024	NASDAQ:AFMD	Affimed NV
03/11/2024	3:05PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
03/06/2024	5:34AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
03/06/2024	5:30AM	GlobeNewswire Inc.	Affimed Announces 1-for-10 Reverse Stock Split	NASDAQ:AFMD	Affimed NV
01/08/2024	3:45PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
01/08/2024	3:05PM	GlobeNewswire Inc.	Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer	NASDAQ:AFMD	Affimed NV
01/08/2024	7:11AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
01/08/2024	7:00AM	GlobeNewswire Inc.	Affimed Announces Leadership Change and Organizational Restructuring	NASDAQ:AFMD	Affimed NV
01/03/2024	5:30AM	GlobeNewswire Inc.	Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck	NASDAQ:AFMD	Affimed NV
12/11/2023	5:10AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
12/11/2023	5:02AM	GlobeNewswire Inc.	Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients	NASDAQ:AFMD	Affimed NV
12/11/2023	5:00AM	GlobeNewswire Inc.	Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)	NASDAQ:AFMD	Affimed NV
12/04/2023	5:30AM	GlobeNewswire Inc.	Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24	NASDAQ:AFMD	Affimed NV
11/30/2023	6:00AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
11/14/2023	5:30AM	GlobeNewswire Inc.	Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress	NASDAQ:AFMD	Affimed NV
11/09/2023	5:30AM	GlobeNewswire Inc.	Affimed Announces Acimtamig as International Nonproprietary Name for AFM13	NASDAQ:AFMD	Affimed NV
11/07/2023	5:30AM	GlobeNewswire Inc.	Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023	NASDAQ:AFMD	Affimed NV
11/03/2023	11:05AM	GlobeNewswire Inc.	Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer	NASDAQ:AFMD	Affimed NV
11/02/2023	8:05AM	GlobeNewswire Inc.	Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting	NASDAQ:AFMD	Affimed NV
11/01/2023	5:30AM	GlobeNewswire Inc.	Affimed to Participate in Upcoming Investor Conferences	NASDAQ:AFMD	Affimed NV
10/04/2023	5:40AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:AFMD	Affimed NV
10/04/2023	5:30AM	GlobeNewswire Inc.	Affimed Announces Listing Transfer to Nasdaq Capital Markets	NASDAQ:AFMD	Affimed NV
09/27/2023	8:05AM	GlobeNewswire Inc.	Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer	NASDAQ:AFMD	Affimed NV
09/21/2023	5:30AM	GlobeNewswire Inc.	Affimed to Present at the Cantor Global Healthcare Conference 2023	NASDAQ:AFMD	Affimed NV
09/12/2023	5:30AM	GlobeNewswire Inc.	Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma	NASDAQ:AFMD	Affimed NV
09/07/2023	5:30AM	GlobeNewswire Inc.	Affimed to Present at the H.C. Wainwright Annual Global Investment Conference	NASDAQ:AFMD	Affimed NV
08/22/2023	4:00AM	GlobeNewswire Inc.	Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability	NASDAQ:AFMD	Affimed NV